STAT News

STAT+: Most cancer drugs approved by European regulators lack a high clinical benefit, analysis finds

Most new cancer medicines approved by European regulators over a recent four-year period do not offer high clinical benefit, a new analysis finds.

By STAT News

1 min read
STAT+: Most cancer drugs approved by European regulators lack a high clinical benefit, analysis finds
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights